A month of Zepbound costs $25 or about $1,000, depending on who is paying

A one-month supply of Zepbound vials runs $349-$699 without insurance, and the injector pens cost about $1,000 before insurance. With insurance coverage, the same month can land as low as $25.

Getting there takes a prescription from a licensed clinician, in person or through telehealth, and the label covers adults with obesity or excess weight who also have at least one weight-related condition such as type 2 diabetes or heart disease. Eli Lilly ships vials and pens to the door through a program called LillyDirect, while the health plan decides the rest through prior authorization or a requirement to try a different medicine first.

Supply was the bottleneck for a stretch, and the manufacturer now says shortages are no longer an issue. What grew in that gap was compounding, pharmacies making their own versions of the drug, which the Food and Drug Administration warns against because those versions have not been tested for safety.

For a household, the distance between $25 and about $1,000 a month is not a discount question, it is whether the prescription gets filled at all. Whether a specific plan pays is a conversation with the insurer and the pharmacy, and the answer moves plan by plan.

Read the full story at Health.com ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.